 Valeo Pharma Inc. TSX:VPH, OTCQB:VPHIF said it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc for the Canadian commercialization of two innovative ophthalmic therapies. Under the agreement, Valeo becomes the exclusive distributor of XIIDRA lifitegrast and SIMBRINZA brinzolamide brimonidine tartrate in Canada, making it responsible for all commercial and medical activities. 